


PPAR Signaling

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to a nuclear hormone receptor superfamily, containing three isoforms (α , β/δ , and γ). PPARs are activated by naturally occurring fatty acids or fatty acid derivatives (e.g. eicosanoids) and play a critical physiological role in the regulation of numerous biological processes, including lipid and glucose metabolism, and overall energy homeostasis. Clinically, PPAR ligands like Glitazones (also known as Thiazolidinediones (TZDs)) are used for treatment of type 2 diabetes by decreasing insulin resistance. In addition, PPARs also have been implicated as modulators of obesity-induced inflammation making them interesting therapeutic targets to mitigate obesity-induced inflammation and its consequences. Heterodimers of PPAR and Retinoid X Receptor (RXR) form important transcription activators which upon binding PPAR response elements (PPRE) can modulate many important cell functions. For example, PPAR α -RXR dimers activate target genes which control peroxisome proliferation, fatty acid metabolism and lipid homeostasis, while PPAR γ -RXR dimers affect adipocyte differentiation, glucose and insulin homeostasis and macrophage function.



Antibodies

Name	Cat. #
PPAR gamma Antibody	3809-100
PPAR gamma Blocking Peptide	3809-BP50
PPAR-alpha Antibody	3585-100
PPAR-alpha Blocking Peptide	3585BP-50

Enzyme

Name	Cat. #
PPAR γ , Human, Recombinant	4371-10

PPAR Agonists

Name	Cat. #
Ciglitazone	1695-5
GW1929	2057-5, 25
GW501516	1971-1, 5
Pioglitazone	1877-5, 25, 100
Rosiglitazone	1559-5, 50,100
Troglitazone	1696-5
WY-14643	2041-10, 50

PPAR Antagonist

Name	Cat. #
GW 9662	1697-5
T0070907	2095-5